Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Go get em Craig! Thanks for doing this as we will soon know the truth and the (-)'s will vanish.
Go Nick and MDIN
Nice! Nick is the man, and I loved every bit of his emails!
Set it and forget it all! The DD did not change, the players have and all games will end with the PR we are waiting for. They may be winning the fight but we will win the war!
Stay Strong SVFC
I am still seeing it under Nicks acct.
https://twitter.com/MedGenlnc
Been here 6 months lost some money on paper but that's all! Day to day fluctuation is not a factor in my game plan. I will be holding when they start phase 2 and PPS will look a lot different. If you watch this board everyday you will go crazy! It WILL happen patience will be the key to the lost treasures...
BMSN
WOOOOOOO HOOOOOOOOO!
BMSN will be life changer in due time.
GLTA
Intellicell Business Model
Presently, IntelliCell processes its SVFC's in a cGTP compliant cellular lab with strict standard operation procedures (SOP's). The initial IntelliCell cellular lab is located in its ambulatory surgical center at 460 Park Avenue, New York, NY;
doctors wishing to use cellular therapy to treat their patients may use the IntelliCell Cellular facilities, equipment and processes. IntelliCell either supplies its cellular products to doctors working for its affiliate Regen Medical PC for the
treatment of their patients or sells the processed SVFC's to outside physicians who treat their patients in the IntelliCell Cellular facility. Since the SVFC's are returned to a patient’s own body in a same-day outpatient procedure, with little or
no risk of disease transfer, rejection, or allergic reaction, IntelliCell believes it can operate under a FDA exempt CFR 1271.15 (b) or PHS 361 CFR 1271.10 (a).
The company's expansion plan is to acquire cash flow positive ambulatory surgery centers in major US markets beginning in 2013 with a target of operating 20 centers by 2016. Each center will generate between $10M to $30M of revenue per annum in traditional surgical procedures such as orthopedics, aesthetic plastic surgery, urology, etc.
IntelliCell will place a cGTP compliant cellular processing laboratory in each surgical facility and offer regenerative medical procedures in addition to the surgical procedures. The company believes an additional $10M to $15M can be generated per annum from the cellular therapies at an average gross profit of
70% from the cellular procedures.
The financial model target is to reach over $600m in combined revenues by 2018. By combining surgical revenues with cell therapy revenues, the company believes it has developed a risk mitigated market entry model and a business model poised for sustainable growth.
Beyond the operation of providing a fully equipped and staffed surgical center for the collection and use of SVFC's with patients, IntelliCell believes there are additional methods the IntelliCell business model can generate value:
• Licensing its technology for international partners and additional areas of clinical development. This could include wound care, cardiac, gastrointestinal (colitis/ileitis), multiple sclerosis and autism to other companies in the regenerative medicine field.
• Establishment of an SVF cellular tissue bank. IntelliCell will market this service to liposuction patients in addition to any patient who might want to store their SVFC's for future use3
• Fees from training and certifying physicians in the use of the IntelliCell process.
FDA
The company has been engaged in discussions with the FDA regarding operational compliance issues and its exemption status position. FDA issued IntelliCell a “Warning Letter” March 13, 2011, based upon a site audit of its previous beta laboratory. The cGTP issues were resolved upon the completion of ntelliCell's new flagship location and opening its cGTP cellular lab.
Biologics
Consulting Group performed an independent quality audit of the new facility The company and its legal and biologic advisors are currently involved with FDA in discussions related to the company's position that it qualifies as an exempt product from regulation as a drug. The primary reasons behind the company's
claim is that the non-structural lipoaspirate is minimally manipulated, no enzyme or chemical is added to the cell population, the cells are not expanded or grown in culture, and the relevant biological characteristics of the cells have not been altered. Discussions are expected to continue throughout 2013 and the company is hopeful that FDA will agree with its position as an exempt product based on the IntelliSonics™ process. Regardless of the final outcome, the company is
prepared to comply fully with any and all regulations.
Clinical Studies
To increase the value of its business model, IntelliCell is in the process of selectively making investments to launch clinical trials so that in the future it can make clinical claims for its cellular product. These clinical studies will be IND/IRB
FDA studies to achieve FDA approval for clinical claims. Areas under consideration include
• Treating osteoarthritis of the knee
• Gingival gum regeneration, both of which have demonstrated safety and
efficacy in published early pre-clinical work
• Wound healing to treat non-healing diabetic ulcers
• Future product candidates include:
o Multiple sclerosis
o Erectile dysfunction
o General dermal regeneration
One of the major advantages of conducting these clinical studies is that since the SVFC's are already used by Regen Medical PC to treat patients, the outcome of 4 the effectiveness of the treatment is already known. This is a significant
difference over traditional pharmaceutical trials where the outcome of the clinical trial is usually not well known.
Competition
There are other companies using lipoaspirate tissue to manufacture stromal vascular fraction. Companies, such as Cytori and Celltex, use an enzyme (collagenese) to separate the SVFC's from the blood vessels in the adipose tissue and they are being regulated by FDA as a drug, due to the fact that the use of enzymes causes significant biologic manipulation. Cytori, Celltex, Tissuegenesis, and others are utilizing a point of care device to produce the cellular product. When factoring in the cost of the capital equipment (as much as $70,000 each) and high disposal cost per case (as much as $1,500), IntelliCell believes it has a superior laboratory system and process in place.
Further, the point of care systems do not produce industry standard batch manufacturing records demonstrating compliance with Quality Assurance that is standard practice in any cGTP or cGMP facility. Specific cell counts, cell viability,
gram staining, endotoxin testing (all part of IntelliCell SOP's) are not included with the point of care systems. The Future
Once the FDA agrees with IntelliCell that it falls under either CFR 1271.15(b) or PHS 361: CFR 1271.10 (a), the business model can be supplemented with placing the IntelliCell Labs into other surgical centers and/or hospitals. This would be a modified franchise model where IntelliCell would operate the labs.
The revenue stream would flow from IntelliCell licensing and/or selling the “IntelliCell” process to the hospital or doctors for use with their patients.
This is how SVFC will make money! And it is already generating royalities : )
Technology Licensing
IntelliCell will license its suite of technology and protocol to physicians or surgery centers for use among their patients.
ICBS Lab Technician runs the process ensuring quality control and GMP & GLP compliance.
Opportunities:
Orthopedics: Over 1 Million Hip and knee replacements, 600,000
back procedures performed annually in the U.S. where SVFs could
potentially mitigate the need for surgery.
Sports Medicine: A $1.3B addressable market and a key corporate
focus with meaningful partnerships already secured.
Periodontal Disease: A $6B addressable market; IntelliCell has recently completed case studies using SVFs in the treatment of gum recession showing no need for grafting
SPORTS MEDICINE
Sports Medicine is a key strategic focus for IntelliCell
as it seeks to build broad brand awareness among
both professional and non-professional athletes.
IntelliCell’s efforts led by Dr. James Andrews of the
Andrews Sports Medicine and Orthopedic Centers.
Planned multi-center clinical study exploring SVF’s
impact on osteoarthritis of the knee.
MARKET OPPORTUNITY
17,000 Professional Athletes in the U.S.
50,000 NCAA Division I Athletes in the U.S.
Millions of amateur athletes and aging boomers
REVENUE MODEL FOR LICENSING
$150,000 in upfront licensing fees for
equipment, installation, and training.Yields high margin revenues for IntelliCell. $1,000 in per procedure fees to IntelliCell.
Two procedures per week per lab generates $100,000 in annual revenues for IntelliCell.
IntelliCell estimates 100 labs will be operational by year-end 2013.
Licensing Partners:
IntelliCell has licensed its Technology to International partners for large upfront payments and ongoing royalties.
SECURED PARTNERS
Licensed by RegenaStem in Canada (operating as IntelliCell
BioSciences of Canada) for $500,000 upfront and a 30% share of
revenues. Licensed by Cell-Innovations, Pty Limited in Australia for $700,000 upfront and a 12.5% share of revenues.
PROSPECTIVE PARTNERS
Middle East led by Saudi Arabia
Thailand
Malaysia
Indonesia
ACTIVE PARTNERSHIP DISCUSSIONS
Wound Care: The Global wound care market generated $6.2B in 2010.
Over the course of the next decade, demand for advanced wound care will increase due to an increasing prevalence of chronic wounds as diabetes and obesity rates increase.
Heart Disease: Cytori, an IntelliCell peer that harvests stem cells from adipose tissue using enzymes, is sponsoring three European clinical trials to evaluate the use of adipose-derived stem and regenerative cells in the treatment of acute myocardial infarction and chronic myocardial ischemia and recently received FDA approval for IDE.
Adipose stem cell heart attack trial data published in the Journal of American College of Cardiology in January 2012.
IntelliCell is in discussion with several partners who may desire a substantially similar solution that leverages IntelliCell technology.
Centers of Excellence
Centers of Excellence are IntelliCell
managed locations where patients can receive SVF treatments.
First Center to open in April 2012 offering cosmetic and dermatologic procedures. Centers of Excellence receives $10,000 per patient per procedure versus $1,000 in the lab
sales model. Centers of Excellence receives $2,500 per
procedure when other physicians utilize the facility.
PLANNED CENTERS
Beverly Hills, CA
Miami, FL
Houston, TX
SVF Cryo-Storage
IntelliCell’s Cryo-Storage Service will create a large stream of high margin recurring revenues. $500 for initial collection.
$200 per dose per year for storage. $1,000 for removal from storage and shipment to physicians for use by patient.
OPPORTUNITY
500,000 liposuction procedures performed annually, an ideal source of customers who have ready access to adipose tissue.
Examining acquisitions and joint ventures opportunities with several prominent cryo-storage companies.
Thanks for the .049's flippers
Hi All,
I believe the fast track is only for Orphan Drug status.
https://en.wikipedia.org/wiki/Orphan_drug
Hold unto your shares all Nick is telling the truth : )
It will come out that Adrian Peterson and RGIII was treated with stem cells and Dr. Andrews performed the surgery.
Dr. Andrews:
Ever Wonder why the BEST Sports Surgeon is on SVFC advisory board?
Stem Cells are the future:
http://www.stack.com/2013/02/05/rgiii-knee-injury/
http://bleacherreport.com/articles/1451061-adrian-petersons-acl-tear-a-closer-look-at-his-injury-and-incredible-recovery
http://www.theandrewsinstitute.com/News/Featured/Article.aspx?id=800806772
Looking for exciting next couple days with this low float monster!
Going to be a good day!
Let's Go!
SVFC
Patientgal,
Are you talking about our Dr. Ichim?????? Wooooooo Hoooooo! I'm drinking one with you!
Thomas E. Ichim, PhD
Chief Scientific Officer and Director of Research
Dr. Ichim is one of the leading authorities in the world on stem cell biology. To date, he has published 82 peer-reviewed articles and is co-editor of the textbook RNA Interference: From Bench to Clinical Translation. He is also inventor on over 30 patents and patent applications. He currently serves as the CEO of Medistem, Inc., was formerly chief of scientific development, and is the scientific founder / co-founder of Medvax Pharma, ToleroTech, bioRASI, and OncoMune.
This may be a good long term investment!
The company's (SVFC) expansion plan is to acquire cash flow positive ambulatory surgery centers in major US markets beginning in 2013 with a target of operating 20 centers by 2016. Each center will generate between $10M to $30M of revenue per annum in traditional surgical procedures such as orthopedics,
aesthetic plastic surgery, urology, etc.
IntelliCell will place a cGTP compliant cellular processing laboratory in each surgical facility and offer regenerative medical procedures in addition to the surgical procedures. The company believes an additional $10M to $15M can be
generated per annum from the cellular therapies at an average gross profit of 70% from the cellular procedures.
The financial model target is to reach over $600m in combined revenues by 2018. By combining surgical revenues with cell therapy revenues, the company believes it has developed a risk mitigated market entry model and a business model poised for sustainable growth.
Beyond the operation of providing a fully equipped and staffed surgical center for
the collection and use of SVFC's with patients, IntelliCell believes there are
additional methods the IntelliCell business model can generate value:
• Licensing its technology for international partners and additional areas of
clinical development. This could include wound care, cardiac, gastrointestinal
(colitis/ileitis), multiple sclerosis and autism to other companies in the
regenerative medicine field.
• Establishment of an SVF cellular tissue bank. IntelliCell will market this
service to liposuction patients in addition to any patient who might want to
store their SVFC's for future use3
• Fees from training and certifying physicians in the use of the IntelliCell
process
Good Morning all SVFCers!
Looking for a great day today as this will soon be a gift to all!
From Intellicell
Kevin
Thank you for taking a stake in Intellicell. We are committed to bringing all shareholders value and look to advance the company to one of the big boards as soon as we can and we are always developing new and better technology and always file patents to protect our IP and as stated in our website we are looking to doing FDA IND for different disease entities.
We have exciting news coming in the new future for all our shareholders.
Steven Victor MD
Chairman/CEO
Intellicell Biosciences Inc
460 Park Avenue 17th Floor
New York, NY 10022
212-249-3050 Regen Medical PC
Cell 917-459-8252
Svictor@intellicellbiosciences.com
www.intellicellbiosciences.com
Www.regenmedicalpc.com
Www.victordermatologyandrejuvenation.com
SVFC
Guess I am not getting more at .0487! Soon this price will look like a treasure.....
Good Morning All!
Just the folks having these procedures done in New York alone will drive this PPS sky high!
Excited and buying this dip! Wont last too much longer folks.
SVFC
I'm liking the way you're thinking here! This would be sweet for any one willing to wait and be patient!
BMSN
The Future Franchising Model:
Once the FDA agrees with IntelliCell that it falls under either CFR 1271.15(b) or PHS 361: CFR 1271.10 (a), the business model can be supplemented with placing the IntelliCell Labs into other surgical centers and/or hospitals. This would be a modified franchise model where IntelliCell would operate the labs.
The revenue stream would flow from IntelliCell licensing and/or selling the “IntelliCell” process to the hospital or doctors for use with their patients.
This may be a good long term investment!
The company's (SVFC) expansion plan is to acquire cash flow positive ambulatory surgery centers in major US markets beginning in 2013 with a target of operating 20 centers by 2016. Each center will generate between $10M to $30M of revenue per annum in traditional surgical procedures such as orthopedics,
aesthetic plastic surgery, urology, etc.
IntelliCell will place a cGTP compliant cellular processing laboratory in each surgical facility and offer regenerative medical procedures in addition to the surgical procedures. The company believes an additional $10M to $15M can be
generated per annum from the cellular therapies at an average gross profit of 70% from the cellular procedures.
The financial model target is to reach over $600m in combined revenues by 2018. By combining surgical revenues with cell therapy revenues, the company believes it has developed a risk mitigated market entry model and a business model poised for sustainable growth.
Beyond the operation of providing a fully equipped and staffed surgical center for
the collection and use of SVFC's with patients, IntelliCell believes there are
additional methods the IntelliCell business model can generate value:
• Licensing its technology for international partners and additional areas of
clinical development. This could include wound care, cardiac, gastrointestinal
(colitis/ileitis), multiple sclerosis and autism to other companies in the
regenerative medicine field.
• Establishment of an SVF cellular tissue bank. IntelliCell will market this
service to liposuction patients in addition to any patient who might want to
store their SVFC's for future use3
• Fees from training and certifying physicians in the use of the IntelliCell
process
About SVFC's competition:
There are other companies using lipoaspirate tissue to manufacture stromal vascular fraction. Companies, such as Cytori and Celltex, use an enzyme (collagenese) to separate the SVFC's from the blood vessels in the adipose tissue and they are being regulated by FDA as a drug, due to the fact that the use of enzymes causes significant biologic manipulation. Cytori, Celltex, Tissuegenesis, and others are utilizing a point of care device to produce the cellular product. When factoring in the cost of the capital equipment (as much as $70,000 each) and high disposal cost per case (as much as $1,500), IntelliCell believes it has a superior laboratory system and process in place. Further, the point of care systems do not produce industry standard batch manufacturing records demonstrating compliance with Quality Assurance that is standard practice in any cGTP or cGMP facility. Specific cell counts, cell viability,
gram staining, endotoxin testing (all part of IntelliCell SOP's) are not included with the point of care systems.
I can see a day when stem cells from these procedures are cryopreserved. Down the road, should you break your arm or your ankle, those cells could be used to help you heal rapidly. I think Cytori's device has enormous potential. I respect the fact that it is targeting CMI with a peak oxygen consumption endpoint along a PMA (device) pathway.
Once the company completes the current phase 2 study successfully, all it will need to do is one modestly sized phase 3 trial. Proving safety is less of an issue with the device pathway, so the pivotal trial's focus is a p-value (statistically valid result) on a relevant endpoint.
Won't hold us Down with all of the things SVFC is working on. Some were set in motion 1-2 years ago and are now hitting and plan coming together for huge revenues.
IIntelliCell BioSciences, Inc. Announces Collaborative Agreement With University Of Florida On Stem Cell And Tissue Repair Research
IntelliCell BioSciences, Inc. Signs Technology Licensing Agreement With Stem Cells 21 Thailand
IntelliCell BioSciences, Inc. Announces Study Published In The Journal of Implant & Advanced Clinical dentistry
IntelliCell BioSciences, Inc. Signs Exclusive Supply And Sale Agreement With Millipore Corporation
IntelliCell BioSciences, Inc. Announces It Has Opened Adipose Tissue Processing Center In West Palm Beach, Florida
The PAWS Pet Company, Inc. Announces Exclusive License Agreement With IntelliCell BioSciences, Inc
IntelliCell BioSciences, Inc. Announces It Has Opened An Adipose Tissue Processing Center In New Orleans
IntelliCell BioSciences, Inc. To Open Tissue Processing Center In Baton Rouge, LA
IntelliCell BioSciences, Inc. Announces Validation Of Technology By Merck Subsidiary
SVFC signs exclusive with PAWS? What a huuuuggggee Market! people care a lot for their pets.
The PAWS Pet Company, Inc. Announces Exclusive License Agreement With IntelliCell BioSciences, Inc
The PAWS Pet Company, Inc. (OTCQB: PAWS) (OTCPK: PAWS) or “the Company”, the innovative pet services company, today announced it has entered into an exclusive license agreement with IntelliCell BioSciences, Inc., “IntelliCell”, (OTCPK: SVFC) a leader in regenerative medicine and the manufacturing of stromal vascular fraction (SVF) containing adipose derived adult stem cells. Per the terms of the agreement, The PAWS Pet Company is to exclusively market and sell IntelliCell’s SVF solution in the veterinary market.
According to Hoovers, the U.S. veterinary services industry has annual revenues estimated at $25 billion.
“This is an important step in the development of the Company,” said Dan Wiesel, Chairman and CEO of The PAWS Pet Company. “This exclusive world-wide license extends our service offering beyond the pet transportation marketplace, into the fast growing market for regenerative medicine for animals. Through our trusted position with both Pet Parents and Veterinarians, we will introduce a technology that we believe will improve the wellbeing of pets.”
Dr. Steven Victor, Chairman and CEO of IntelliCell added, “We are pleased to be working with The PAWS Pet Company in bringing our leading SVF solution to the treatment of animals. The benefits of SVF in providing stem cell counts and viability checks for each specimen processed, as well as enhanced quality and quantity of the stem cells produced, will now be available to pets.”
Dr. Jeff Werber, Director of Veterinary Services with The PAWS Pet Company commented, “SVF is a proven treatment for a number of conditions including osteoarthritis, tendon repair, ligament injuries and other traumatic and degenerative diseases. The higher cell count from a smaller tissue sample means that Pets have a faster road to recovery with SVF compared to legacy enzyme-based stem cell treatments.”
How about another Resume for one of our Board Dr.s:
Intellicell Biosciences Company believes the market for non-enzymatic stromal vascular therapy for the professional sports medicine market is in excess of $1 Billion
Frederic Nicola, MD from D.I.S.C. Sports & Spine Center, who is the team doctor for the Oakland Raiders and Los Angeles Kings. - See more at: http://investorstemcell.com/stem-cell-research/intellicell-biosciences-inc-announces-the-addition-to-medical-advisory-board
Frederic G. Nicola, M.D.
Diplomate, American Board of Orthopedic Surgery
Member, American College of Occupational and Environmental Medicine
Specializing in Orthopedic Surgery and Sports Medicine
Joint Reconstruction and Arthroscopy
http://www.garlandpr.com/Nicola%20CV.pdf
Do the new investor's really want to be sitting on the sidelines when this takes off? This all takes time, SVFC fell from the Nasdaq as they were working on Patents, new Clinical trials, Licensing contracts etc... They are back and time to move back up!
IntelliCell's fat-derived stem cells termed "technological breakthrough" in Forbes
IntelliCell BioSciences (OTCBB:SVFC) has made a technological breakthrough into the regenerative medicine field, according to blog entry in Forbes.
The company, through its proprietary technology, processes stromal vascular fraction (SVF) stem cells, derived from one's own body fat.
Fat stem cells are now the cutting edge, with many doctors and companies researching the use of them for anti-aging effects, as well as for the treatment of more serious conditions like arthritis, congestive heart failure, gum recession, and wound healing.
IntelliCell's SVF cells can be used to treat certain conditions, or rejuvinate damaged tissue and cell function. The company, which under the FDA is authorized to commercially sell its SVF cells, has also applied for a patent on its use of ultrasonic cavitations to break up fat cells, which increases the number of SVF stem cells that can be extracted from just two ounces of fat to between 500 million and 1.4 billion, Forbes said.
The company's technique takes approximately 30 minutes, costs less than other stem cell extraction products, and the stem cells can be returned to a patient’s doctor in the same day.
"It is very apparent that a person’s fat cells are the best source of stem cells, which are stored inactively in one’s fat tissues, for use in the fast growing field of regenerative medicine," IntelliCell CEO, Dr. Steven Victor told Forbes.
Forbes noted that IntelliCell's technology can produce an average of 10 times the number of stem cell-containing SVF cells as traditional methods, which require the use of enzymes, according to a study of the company's technology by a unit of Merck AG.
Indeed, these fat stem cells have similar potential to embryonic stem cells in their pluripotency, and are from a source that involves no moral or ethical issues, as well as no chemical additives required for digestion of the tissue.
In the aesthetic world, the use of autologous adipose, or fat, stem cells has become widely accepted in Europe and Asia. Since the US FDA published its laws on autologous stem cells in mid-2009, the field has expanded rapidly.
IntelliCell has also treated more than 100 patients this year alone, Forbes said, including the wife and daughter of MAZ Capital Advisors' president, and IntelliCell shareholder, Walter Schenker. Each underwent a successful treatment at an IntelliCell lab for knee ailments, Forbes cited.
This is an awesome spot to be in! Good Luck to all Today.
IntelliCell BioSciences Announces Frederick Frank as Executive Advisor to Board of Directors
Dr. Steven Victor, CEO of IntelliCell, stated "We are very pleased to have Mr. Frank join our organization and gain access to his biotechnology expertise and leadership. He has made a tremendous impact on our industry and specifically for the companies he has chosen to be affiliated with. We look forward to his counsel as we strive to achieve new landmarks in regenerative medicine."
Added Mr. Frank "Like many heralded advances in the life sciences field, the early promise and potential creates pronounced enthusiasm. Often the realization of that promise takes longer and is more complex than forecasted. And, inevitably, disappointment sets in. The promise of utilizing therapeutic stem cells is just such an example. But now it's here. Under the leadership of Dr. Steven Victor at IntelliCell BioSciences, the promise of tomorrow is a reality today."
Mr. Frank joined Peter J. Solomon in 2009 from Barclays Capital where he was Vice Chairman. He began his investment banking career at Smith, Barney & Co. Inc. in 1958, where he attained the positions of Co-Head of Research, Vice President and Director. Subsequently he joined Lehman Brothers, Inc., in 1969, as a partner. At Lehman, Mr. Frank provided investment banking services to an extensive number of companies in the pharmaceutical, biotechnology, healthcare services, medical device and nutraceutical industries, and was involved in hundreds of financings, strategic alliances and merger and acquisition transactions in the global healthcare industry. Mr. Frank is a director of Landec Corporation, a publicly-traded material science company, and formerly a director of Pharmaceutical Product Development, Inc., a publicly-traded contract research organization. Mr. Frank previously served as Chairman of the Board of Epix Pharmaceuticals, Inc., a publicly-traded pharmaceutical company. He is Chairman of the National Genetics Foundation, a past director of the Salk Institute, a member of the Pharmaceutical Executive Magazine advisory board and the Journal of Life Sciences, the former Chairman of the Board of The Irvington Institute for Immunological Research, a former member of the Advisory Board of The Harvard School of Public Health, a past member of the advisory board of the Johns Hopkins Bloomberg School of Public Health and he serves on the Advisory Board of the Massachusetts Institute of Technology Center for Biomedical Innovation. He serves on the Yale School of Management Advisory Board. Mr. Frank holds a B.A. from Yale University and an M.B.A. from the Stanford Graduate School of Business.
I believe this may be the path to Pfizer. IMO
Dr. Fisch, “I believe that the promise of Regenerative Medicine for patients suffering from a number of urological disorders including erectile dysfunction may become an important part in the practice of medicine. This is an exciting time in medicine and I am looking forward to working with cutting edge technologies like IntelliCell’s and improving the clinical outcomes of my patients.” - See more at: http://investorstemcell.com/stem-cell-research/intellicell-biosciences-announces-the-addition-of-harry-fisch-md-as-director-of-urology/#sthash.u2UWR361.dpuf
http://www.harryfisch.com/about-harry-fisch.html
TCA Global Credit Master Fund Closes on $2 MM Financing facility for IntelliCell BioSciences Inc.
TCA Global Credit Master Fund today announced it has entered into a $2 Million CEF; committed equity facility with IntelliCell BioSciences (SVFC.PK). Under the terms of the Agreement, TCA Fund will supply the financing in a series of pre-set tranches to the company, with the initial drawdown set at USD 500,000.
The CEF has been provided through TCA Global Credit Master Fund (“TCA Fund”), which seeks to provide financing to small, growing, private and listed companies.
TCA Global Credit Master Fund has provided financing to allow IntelliCell BioSciences, the company, to spur its growth, as well as allow them to take advantage of additional opportunities in their field of regenerative medicine.
Dr. Steven Victor, the Chairman and CEO of the company has a unique approach, “IntelliCell™ is pioneering a new proprietary medical process that results in acquiring Vascular Fraction Cells (VFC). VFC is also known as stromal vascular fraction. VFC cells are known to contain significant numbers of various cell types including adult stem cells, endothelial cells, fibroblast cells, red blood cells, and much more. VFC type cells are in research projects and in clinical trials around the world.”
Based in NY, NY “IntelliCell was formed to take a leading role in the rapidly expanding regenerative medicine field. IntelliCell is fully committed to an ethical and supportive role in providing the tools to physicians and patients to fight some of the most serious disease conditions with very high levels of unmet clinical needs.”
TCA Fund Management Group manages the TCA Global Credit Master Fund and acts as an advisor to countless small companies from its offices in the United States, United Kingdom, and Australia. TCA Fund is a short duration, absolute return fund specializing in senior secured lending to small, mainly listed companies in the U.S., Canada, Western Europe and Australia. The team has a level of domestic and cross-border expertise, long-standing experience, and funding innovations, as is reflected in the number of transactions completed. This is a specialist business with an investment angle which fills an important finance gap in many leading markets. TCA Global Credit Master Fund provides a unique conduit for investors seeking steady, uncorrelated returns in the SME universe.
http://www.bafitis.com/stem_cell_therapy_bafitis.asp
WHAT CONDITIONS HAVE BEEN TREATED BY ADIPOSE-DERIVED STEM CELLS?
The United States has been slightly behind in the clinical use of stem cells, but veterinarians have been using equine stem cells derived from fat to correct aging or damaged tendons in horses for over seven years with amazing results! In humans, stem cells have been utilized as follows in the United States:
a. Dermal injections for dermal regeneration with improved lines and wrinkles.
b. Dermal injections for acne scars.
c. Dermal injections for burns and ulcerated wounds.
d. Addition of stem cells to harvested fat for greater take, regeneration, and volumizing of the face and body.
e. These cells have also been successfully utilized in the knee, elbow, and hands in terms of injections for arthritis.
f. Knee injections for cartilage repair or improvement for cartilage loss/ damage.
A quote from Dr. James Andrews:
“I am dramatically impressed with IntelliCell’s proprietary non-enzymatic method for manufacturing Stromal Vascular Fraction from a person’s own adipose tissue,” said Dr. Andrews. “The amount of SVF cells that this process creates will enable physicians to treat sports injuries without the need for culturing the cells or adding enzymes. We are looking forward to employing this process at our own Institute and to conduct further research with the IntelliCell team on this exciting regenerative medicine.”
http://www.businesswire.com/news/home/20120109006237/en/CORRECTING-REPLACING-IntelliCell-Biosciences-Announces-Addition-World
Dr. James Andrews treated Adrian Peterson and Robert Griffin III with Stem cells in their recent surgeries. Dr. Andrews sits on our Medical Advisory Board and believes Stem Cells are the future!
There are physicians who have also utilized stem cells via IV drip for osteoarthritis and improvement in pain from inoperable joint/spine disease.
We were here just 1 year ago. This Company is heading back to the old days with more and better Technology along with Licensing agreements!
Shares of the tightly held IntelliCell BioSciences, Inc. (OTCQB: SVFC.PK) (Pinksheets: SVFC.PK) have been starting to climb since announcing their arrival as a disruptive stem cell harvesting technology firm just a few short weeks ago. The regenerative medcine industry is starting to take notice, but it appears investors are too.
BioMedReports first told readers about this company in a report from the Rodman & Renshaw Conference, and shares have climbed from $3 to over $4 since then. Even in these very anemic market conditions, speculators are starting to take positions after hearing about the potential of the IntelliCell platform.
In additon, the Company just announced that they executed an exclusive supply and sale agreement with Millipore Corporation, a global leader in innovative tools and technologies for bio-manufacturing and life science research, to sell and distribute the guava® flow cytometry platform into the area of stromal vascular fraction.
Forbes: Human Body’s Fat Seen As best Source of Stem Cells For Regenerative Therapies
Intellicell Biosciences, Inc.
4.10 - (0.00%)
Intraday 3 Month 6 Month 1 Year
The collaboration with Millipore is expected to streamline the development of IntelliCell’s tissue processing centers throughout the United States as it continues to expand and experience growth in demand for the cells it is able to source from fatty tissue.
As we understand it, the company is rapidly expanding the number of centers throughout the United States and multiple positive announcements should follow. These very unique centers will offer patients the opportunity to use their own adipose (fat) stem cells for treatments as prescribed by their own doctors. Under FDA 361, patients are allowed to use their own stem cells for just about any indication, so long as the use of those cells is autologous (a situation in which the donor and recipient are the same person), the stem cells are minimally manipulated, and the procedure takes place during the same office visit. Even without FDA approval- which can take years- IntelliCell™ BioScience aims to work within FDA 361 guidelines and claims that they are fully FDA compliant on their website and presentation materials.
As we told you in our report, this company represents a game changing opportunity for U.S. based patients to undergo various stem cell therapies using their own stem cells without having to travel abroad or wait for further FDA approvals.
We expect that this company- already one of the only true revenue generating stem cell plays in the market- will surpass the $30+ million in revenues generated last year by a privately held company based in Plymouth, Mass called Harvest Technologies Corporation. That company was in the process of commercializing a far more painful (and arguably less effective), point-of-care technology with doctors. Using the Harvest Technology platform, physicians harvested stem cells from a patient’s own bone marrow. Harvest was recently acquired by a U.S. subsidiary of Japan’s Terumo Corporation — one of the world’s leading medical device manufacturers with $3.4 billion in sales and operations in more than 160 countries in a stock for stock transaction worth $70 million.
The market potential for IntelliCell BioSciences is far more attractive, and we are hearing rumors that various sports franchises may be looking to treat the injuries of pro athletes using the IntelliCell platform within the offices of their own team doctors. No surprise if true, since they have pro sports teams physicians on their advisory board.
The use of autologous adipose stem cells for a growing variety of indications may appear new and exciting in medicine here in the U.S, but the aesthetic world the use of autologous adipose stem cells has become widely accepted in Europe and Asia. Since the middle of 2009 when the U.S. FDA published its laws on autologous stem cells the field has expanded rapidly. If you are looking for a stem cell play that isn’t going to make you wait 5+ years for FDA approval, this may be it.
Said IntelliCell Chairman and CEO, Dr. Steven Victor about this week’s news development: ”This is a phenomenal step in the right direction for our company and we welcome the opportunity to work with Millipore. The exclusive agreement with Millipore to supply and sell their cutting-edge guava flow cytometer, combined with our proprietary process which has achieved unprecedented yields of stromal vascular fraction without the use of chemical additives such as enzymes, gives us a highly significant advantage in creating the gold standard for the separation of SVF from fat. As the only company to use precise methods of counting cells and checking specimens for cell viability, dead cells, or debris, this is yet another milestone in our quest to become market leader in the area of separation of SVF, which greatly differentiates us from all other companies that manufacture these cells.”
Again. This company is a game changer for the entire stem cell sector. Start your own DD and read more about it ahead of others and more positive developments.
Good Morning to all SVFCers!
Looking for a solid day today with a few high powered whales coming in.
Lets get ready to rumble.....
Even involved in the Dentistry field
Stem cells aid in treating gingival recession
Adding stromal vascular fraction (SVF) containing adipose-derived adult stem cells to existing tissue-regeneration therapies appears to enhance the treatment of gingival recession.
The single-center study, which included seven female patients and one male patient ranging from 23 to 45 years of age with gingival recession, showed that combining a collagen matrix with proprietary SVF adipose processing techniques developed by IntelliCell Bioscience may be a viable alternative to treating gingival recession. In addition, it may eliminate the need for invasive harvesting of periodontal tissue, according to the study authors.
By the end of the six-month prospective study, conducted by private practitioners in New York and Texas, the mean increase in root coverage was 87% for the patients treated. In addition, 66% of treated patients achieved 100% root coverage. These numbers indicate that gingival recession was reversed, with gingival tissue growing back over the root area without having to transplant tissue from another part of the mouth into the gumline, the researchers noted. Post-treatment, patients reported little or no pain and swelling.
Gingival recession is a significant issue in dentistry, and IntelliCell is offering a noninvasive treatment that minimizes patient discomfort and improves outcomes, noted Steven Victor, IntelliCell chairman and CEO, in a press release.
Dr. Andrews:
Ever Wonder why the BEST Sports Surgeon is on SVFC advisory board?
Stem Cells are the future:
http://www.stack.com/2013/02/05/rgiii-knee-injury/
http://bleacherreport.com/articles/1451061-adrian-petersons-acl-tear-a-closer-look-at-his-injury-and-incredible-recovery
http://www.theandrewsinstitute.com/News/Featured/Article.aspx?id=800806772
Here is the link to an Executive Summary:
http://proactivecapital.com/wp-content/uploads/2013/02/imtellicellfactsheet.pdf
Really good to see the CEO discussing the promise of this sleeping giant SVFC.
This explains some of Intellicell's Business overview:
Waiting on this clinical trial to start. Patents, Clinicals,Licensing, Royalties... GO SVFC.
IntelliCell BioSciences has completed the preclinical protocols in anticipation of beginning a clinical trial for osteoarthritis of the knee under an FDA investigational new drug application in mid-2013. The company provides product today to ReGen Medical, and in doing so is building fantastic database of patient experience that will be used to focus on clinical applications.
Anyone want to go to the 2014 Stem Cell conference?
Robert J. Sexauer, Executive Vice President Clinical Development will be speaking on behalf of Intellicell Biosciences.
http://www.triconference.com/cell-therapy
3:20 Designing In-Human Clinical Studies for Cellular Therapy Applications
Robert J. Sexauer, Executive Vice President, Intellicell Biosciences
The talk will focus on the need to harmonize all of the stakeholder groups involved in clinical studies and what type of issues and challenges to expect. I will discuss clinical studies that have been completed and newer trials in development.
Mr. Sexauer has been in the medical technology industry since 1979 and has served in a series of executive corporate positions with a specialization in international clinical, corporate and product development. In 2006, he formed InterMark Associates Ltd., a London based consulting organization focused on the regenerative medicine industry. Among projects undertaken included a turn around as CEO of a California based nanotechnology company that resulted in a settlement with the SEC and redirection of the company's business. Also, Mr. Sexauer directed the first ever in human clinical trial utilizing two autologous cell lines for regenerative medicine. Prior to InterMark, he was responsible for the corporate launch of Isolagen Europe, Ltd. Isolagen developed a pioneering regenerative medicine autologous cellular application for the anti-aging and dermal regeneration market.
Mr. Sexauer has worked extensively outside the United States while also directing mergers and acquisitions at the corporate level and has been a featured guest lecturer at DePaul University in the graduate school of International Marketing. He has also been a featured speaker at national conferences in the medical and information technology sectors addressing market conditions and valuations for mergers and acquisitions.
Robert J. Sexauer, EVP of Clinical Development, stated, "Much as organ donation has saved many, many lives, this process can lead to the development of new lifesaving treatments."
IntelliCell recognizes that SVF therapies are an important part in the future of Regeneration Medicine.
According to BioInformant Worldwide LLC, "There is conclusive evidence that entering the stem cell research products market is fiscally worthwhile. Full-year 2011 analysis determines the size the stem cell research products market to be $2.59 billion, and the stem cell therapies market to be $3.13 billion, for a total of $5.72 billion. In addition, both markets are growing with double-digit growth. Producing stem cell research products thus represents a massive profit opportunity for research supply companies."
We were also guests for the ISSUU Stem Cell Summit in Houston:
Page 65 is our write-up.
This summit was about analysis and market forecasts for 2012-2022
http://issuu.com/rrypublications/docs/scs12_executive_summary?e=3996674/3784571